CMS approves ADLT status for Guardant Health’s Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision.
Latest Ratings for GH
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Wells Fargo | Maintains | Overweight | |
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | Citigroup | Maintains | Buy |
